"Going to be good buying at some stage surely?"
Possibly.
After all, everything has a price.
But at some 10.5x EV/EBITDA (which is where is stock is now trading - even after today's sahre price crunch) that point of buying is still a way off, in my view.
Based on an EV/EBITDA multiple of 8x (which is the maximum I suspect the market will now want to pay for this business given this debacle) and even using $60mpa of EBITDA (generously ahead of FY17's implied EBITDA guidance of between $52m and $53m), this works out to an Enterprise Value for the business of $480m.
Netting off the $50m of Net Debt leaves an equity value of $430m.
In per share terms, that's a share price of $2.15.
And that price level, I think, merely represents fair value.
In order to actually make an investment on under-valuation grounds would require a share price closer to $1.70 (equivalent to 6.5x EV/EBITDA), in my opinion.
- Forums
- ASX - By Stock
- ISD
- Ann: Isentia AGM Chairman and CEO Addresses and Trading Update
Ann: Isentia AGM Chairman and CEO Addresses and Trading Update, page-21
Featured News
Add ISD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online